Uterine leiomyomata are the most widely recognized considerate tumors of the gynecologic tract affecting up to 80% of ladies by 50 years old. It is settled that these tumors are the main source for hysterectomy with an expected all out money related weight more noteworthy than $30 billion every year in the United States. Be that as it may, for the lady who wants future fruitfulness or is a poor careful up-and-comer, conclusive administration with hysterectomy isn't an ideal administration plan. Commonplace gynecologic indications of leiomyoma incorporate fruitlessness, irregular uterine dying (AUB)/overwhelming menstrual dying (HMB) as well as intermenstrual dying (IMB) with coming about iron-inadequacy weakness, pelvic weight and torment, urinary incontinence, and dysmenorrhea. The dismalness brought about by these tumors is legitimately inferable from increments in tumor trouble. Strikingly, leiomyoma cells inside a tumor don't quickly multiply, but instead the expansion in tumor size is auxiliary to creation of an over the top, stable, and unusual extracellular lattice (ECM) made of disrupted collagens and proteoglycans. Therefore, clinical administration ought to incite leiomyoma cells toward disintegration of the extracellular grid, just as stopping or hindering cell multiplication. In this, we survey the present writing with respect to the clinical administration of uterine leiomyoma.